Estradiol valerate and dienogest in hormonal contraception. Acceptability and effectiveness in real clinical practice
https://doi.org/10.21518/2079-701X-2018-13-34-38
Abstract
The combined hormonal contraceptives are now one of the most effective methods of preventing unwanted pregnancies. They provide high contraceptive reliability, accessibility and ease of use, reversibility of effects, safety of use. Modern hormonal contraceptives provide additional therapeutic and prophylactic effects in various conditions. A new combined oral contraceptive Qlaira® was developed in the course of thorough scientific studies. The article presents the experience in using a combined hormonal contraceptive containing estradiol valerate and dienogest – Qlaira® (E2V/DNG). The observations showed high contraceptive effectiveness, acceptability and tolerability.
About the Authors
E. R. Dovletkhanova
Kulakov National Medical Research Centre for Obstetrics, Gynaecology and Perinatology
Russian Federation
Russian Federation
V. N. Prilepskaya
Kulakov National Medical Research Centre for Obstetrics, Gynaecology and Perinatology
Russian Federation
Russian Federation
References
1. Guidelines for outpatient care in obstetrics and gynecology. Edited by Serova VN, Sukhikh GT, Prilepskoy VN, Radzinsky VE. 3rd edition, revised and supplemented, GEOTAR-Media. 2016. Pages 885-894.
2. Clinical guidelines for obstetrics and gynecology. Edited by Savelieva GM, Serova VN, Sukhikh GT. 4th edition, revised and supplemented, GEOTARMedia, 2016, 1024 pages.
3. Prilepskaya VN, Mezhevitinova EA, Nazarova NM et al. Hormonal contraception. Moscow, GEOTAR-Media, 256 pages, 2011.
4. Comprehensive evaluation of the efficacy, tolerability and safety of the combined hormonal third-generation contraceptive. Mezhevitinova EA, Burlev VA, Nabieva KR, Ilyasova NA, Inozemtseva YeA. Meditsinsky Sovet. 9, 2015: 54–61.
5. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. Geneva: World Health Organization, 2004.
6. Heavy Menstrual Bleeding. Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention. https://www.cdc.gov/ncbddd/women/menorrhagia.html/.
7. Ahrendt HJ et al. Contraception, 2009; 80(5): 436–444.
8. Laura M. Borgelt, PharmD and Chad W. Martell, PharmD. Estradiol Valerate/Dienogest: A Novel Combined Oral Contraceptive. Clinical Therapeutics, 34, 1, 2012: 37–45.
9. Nappi RE, Terreno E, Sances G, Martini E, Tonani S, Santamaria V, Tassorelli C, Spinillo A. Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). Contraception. 2013 Sep; 88(3): 369–75. doi: 10.1016/j.contraception.2013.02.001. Epub 2013 Feb 28.
10. Fast Facts for Your Health: Menorrhagia. National Women’s Health Resource Center (NWHRC), Washington, D.C. http://www.healthywomen.org.
11. Briggs P, Serrani M, Vogtländer K, Parke S. Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study. Int J Womens Health. 2016 Sep 15; 8: 477-487. Collection 2016.
12. Macìas G, Merki-Feld GS, Parke S, Mellinger U, Serrani M. Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study. J Obstet Gynaecol. 2013 Aug; 33(6): 591-6. doi: 10.3109/01443615.2013.800851.
13. Munro M.G., Critchley H.O., Broder M.S. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductiveage. FIGO Working Group on Menstrual Disorders. Int J Gynaecol Obstet. 2011, 113: 3–13.
14. Macìas G1, Merki-Feld GS, Parke S, Mellinger U, Serrani M. National Collaborating Centre for Women’s and Children’s Health. National Institute for Health and Clinical Excellence (NICE). Heavy menstrual bleeding. London: Royal College of Obstetricians and Gynaecologists Press; 2007.
15. Heavy menstrual bleeding. Quality standard. NICE /nice.org.uk/guidance/qs47. 2013.
16. Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism. Vincenzo De Leoa, Franca Fruzzettib, Maria Concetta Musacchioa, Valeria Scolaroa, Alessandra Di Sabatinoa, Giuseppe Morgantea. Contraception, 2013, 88: 364–368.
17. Phillip CS, Faiz A, Dowling NF, Beckman M, Owens S, Ayers C, Bachmann G. Development of a screening tool for identifying women with menorrhagia for hemostatic evaluation. American Journal of Obstetrics & Gynecology 2008; 198: 163.e1–163.e8.
18. Ahrendt H-J, Makalova D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a 7-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyles tradiol/ levonorgestrel. Contraception 2009; 80: 436-44.
Review
For citations:
Dovletkhanova ER, Prilepskaya VN. Estradiol valerate and dienogest in hormonal contraception. Acceptability and effectiveness in real clinical practice. Meditsinskiy sovet = Medical Council. 2018;(13):34-38. (In Russ.) https://doi.org/10.21518/2079-701X-2018-13-34-38
Views:
852
Email this article 